30 Publications (Page 1 of 2)
2024
Cholesterol Quantification for C57Bl/6J mice
Notes and raw data. figshare
Notes and raw data. figshare
REV-ERB activation as a novel pharmacological approach for treating inflammatory pain
REV-ERB activation as a novel pharmacological approach for treating inflammatory pain. figshare
2023
Data from Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
Data from Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
REV-ERB activation as a novel pharmacological approach for treating inflammatory pain.
Makhija, Sangeet⋅Griffett, Joshua D⋅Veerakanellore, Giri Babu⋅Burris, Thomas P⋅Elgendy, Bahaa and Griffett, Kristine
Frontiers in pharmacology, vol. 14, pp. 1171931, 2023. | Journal Article
Supplemental Figures S1-S9 from Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
Supplemental Figures S1-S9 from Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
2022
Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists
Griffett, Kristine⋅Hayes, Matthew⋅Bedia-Diaz, Gonzalo⋅Appourchaux, Kevin⋅Sanders, Ryan⋅Boeckman, Michael P.⋅Koelblen, Thomas⋅Zhang, Jinsong⋅Schulman, Ira G.⋅Elgendy, Bahaa and Burris, Thomas P.
ACS Chemical Biology. | Journal Article
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Metabolites. | Journal Article
Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential Alternative
ACS Pharmacology & Translational Science. | Journal Article
2021
Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy
Kuehm, Lindsey M.⋅Khojandi, Niloufar⋅Piening, Alexander⋅Klevorn, Lauryn E.⋅Geraud, Simone C.⋅McLaughlin, Nicole R.⋅Griffett, Kristine⋅Burris, Thomas P.⋅Pyles, Kelly D.⋅Nelson, Afton M.⋅Preuss, Mary L.⋅Bockerstett, Kevin A.⋅Donlin, Maureen J.⋅McCommis, Kyle S.⋅DiPaolo, Richard J. and Teague, Ryan M.
Cancer Immunology Research, vol. 9, pp. 227–238. | Journal Article
Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy. Cancer Immunology Research
2020
REV-ERB agonism improves liver pathology in a mouse model of NASH
PLOS ONE. | Journal Article
REV-ERB Agonism Improves Liver Pathology in a Mouse Model of NASH. []
The Orphan Nuclear Receptor TLX Is a Receptor for Synthetic and Natural Retinoids
Cell Chemical Biology. | Journal Article
2019
Development of novel liver?X?receptor modulators based on a 1,2,4-triazole scaffold
Goher, S.S.⋅Griffett, K.⋅Hegazy, L.⋅Elagawany, M.⋅Arief, M.M.H.⋅Avdagic, A.⋅Banerjee, S.⋅Burris, T.P. and Elgendy, B.
Bioorganic and Medicinal Chemistry Letters, vol. 29, pp. 449-453. | Journal Article
Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. Bioorg Med Chem Letters
2018
Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease
Sengupta, M.⋅Griffett, K.⋅Flaveny, C.A. and Burris, T.P.
ACS Pharmacology and Translational Science, vol. 1, pp. 50-60. | Journal Article
Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. ACS Pharmacol Transl Sci.
2016
Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease
Griffett, Kristine and Burris, Thomas P.
Biochemical and Biophysical Research Communications, vol. 479, pp. 424–428. | Journal Article
2015
Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis
Flaveny, Colin A.⋅Griffett, Kristine⋅El-Gendy, Bahaa El-Dien M.⋅Kazantzis, Melissa⋅Sengupta, Monideepa⋅Amelio, Antonio L.⋅Chatterjee, Arindam⋅Walker, John⋅Solt, Laura A.⋅Kamenecka, Theodore M. and Burris, Thomas P.
Cancer Cell, vol. 28, pp. 42–56. | Journal Article
